Given the divergent functionalities of distinct CK1 isoforms and their variable contributions to tumorigenesis, the development of strategies that can selectively inhibit isoforms relevant to specific tumor types becomes imperative. The gene discussed is CSNK1A1; the disease is neoplasm.